Which ASX 200 company director just sold $480 million worth of shares?

The mammoth trade follows the release of hundreds of millions of ASX shares from voluntary escrow post-merger.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chemist Warehouse co-founder Jack Gance has just sold $480.8 million worth of Sigma Healthcare Ltd (ASX: SIG) shares.

The mammoth transaction was revealed in a 'Change of Director's Interest Notice' that Sigma lodged with the ASX this week.

According to The Australian, Gance hired Macquarie Capital to orchestrate the off-market sale.

Gance sold 155.1 million Sigma Healthcare shares for $3.10 per share.

A surprised and curious male investor drinks black coffee while reading the latest news on rising ASX shares in the newspaper

Image source: Getty Images

Why did Gance sell 155 million Sigma Healthcare shares?

The motivation for Gance's trade is unknown.

However, it occurred within 24 hours of 157.9 million shares belonging to Gance being released from voluntary escrow.

The trade occurred last Thursday, 24 hours after about 558.1 million Sigma Healthcare shares were released from voluntary escrow.

Those shares belong to Gance and his fellow Chemist Warehouse co-founders, Sam Gance and the CEO, Mario Verrocchi.

Sigma and Chemist Warehouse announced their merger in December 2023, and the deal was completed on 12 February this year.

The trio entered a voluntary escrow arrangement at the time of the merger's completion.

In a statement on the day the merger was completed, Sigma Healthcare said the trio had entered a voluntary escrow arrangement because they "are committed to the long-term value creation opportunities available to Sigma following implementation of the Scheme".

In total, 5.6 billion Sigma Healthcare shares were put into voluntary escrow for the trio.

There were two periods of escrow.

The First Period was defined as between the merger completion and the earlier of 31 August or the close of trading on the day Sigma Healthcare released its FY25 results.

This First Period of escrow involved about 558.1 million Sigma Healthcare shares.

The Second Period is between the end of the First Period and the earlier of either 31 August 2026 or the close of trading on the day Sigma releases its FY26 results.

This Second Period applies to 90% of the escrowed Sigma Healthcare shares.

Sigma Healthcare released its FY25 results last Wednesday, 27 August, which signalled the end of the First Period of escrow.

The Australian reports that Jack Gance's $480.8 million sell-off occurred after the close of trading on Thursday, 28 August.

Is the $480 million sell-off cause for concern?

Despite the mega sale, Jack Gance still has plenty of skin in the game at Sigma Healthcare.

Following the transaction, Gance still holds more than 1.42 million Sigma Healthcare shares, equating to a 12.34% stake.

The Sigma share price is $3.08, down 0.3% on Thursday, while the S&P/ASX 200 Index (ASX: XJO) is up 0.7%.

Sigma Healthcare is the ASX 200's second-largest healthcare stock with a market capitalisation of $35.67 billion.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Australian Clinical Labs delivers profit growth and stronger margins in FY26

Australian Clinical Labs’ FY26 earnings reveal profit growth and margin improvements despite market headwinds.

Read more »

medical research laboratory assistant examines solutions in test tubes
Healthcare Shares

CSL shares are rallying. Could tomorrow's results pour fuel on the fire?

One strong month isn't enough. CSL needs earnings recovery to follow.

Read more »

A man with a perplexed expression on his face scratches his head.
Healthcare Shares

4DMedical shares are up 670% — but why have they halved?

Can the company turn its commercial momentum into another explosive share-price rebound?

Read more »

Businesswoman with a pleased smile reading on her laptop at a desk in the office with a look of satisfaction.
Healthcare Shares

Are CSL shares dirt cheap and a strong buy?

There is plenty for CSL to prove next week. The current valuation is why I am still interested.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »